Abstract: To inhibit binding of the influenza Avirus to the host cell glycocalyx, we generate multivalent peptide-polymer nanoparticles binding with nanomolar affinity to the virus via its spike protein hemagglutinin. The chosen dendritic polyglycerol scaffolds are highly biocompatible and well suited for am ultivalent presentation. We could demonstrate in vitro that by increasing the size of the polymer scaffold and adjusting the peptide density,viral infection is drastically reduced. Such ap eptide-polymer conjugate qualified also in an in vivo infection scenario.W ith this study we introduce the first noncarbohydrate-based, covalentlylinked, multivalent virus inhibitor in the nano-to picomolar range by ensuring lowp eptideligand density on alarger dendritic scaffold.
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Multivalent binding to the host cell surface is ac ommon strategy of enveloped viruses as influenza Avirus (IAV). IAV binds to the host cell surface via its trimeric spike protein hemagglutinin (HA), which recognizes sialic acids (SA) on the glycocalyx of cellular membranes. [1, 2] Despite the low binding affinity of individual hemagglutinin receptor binding sites to SA (ca. 2mm), as table adhesion originates from multiple ligand-receptor binding events between the virus (0.02-0.04 HA nm À2 )a nd the SA glycoconjugates on the cell surface (0.5-2 SA nm À2 ). [3, 4] Building upon this naturally occurring multivalent binding mechanism, synthetic multivalent entry blockers were introduced in the 1990s by Whitesides and co-workers. [3, [5] [6] [7] High molecular-weight scaffolds displaying al arge number of low affinity SA derived ligands were used to achieve high HA avidity.Over the years several carrier systems were employed as scaffolds ranging from polymers, [6, 8, 9] dendrimers, [10] [11] [12] [13] liposomes, [5, 14] proteins, [15] to gold nanoparticles. [16] Them ost affine binders reported to date consist of SA tethered to linear polyacrylamide polymers. [6] Although they have ahigh inhibitory potential, polyacrylamide-based inhibitors and their degradation products often show high cytotoxicity. [6, [17] [18] [19] [20] Polyamidoamine (PAMAM) dendrimers have also been used for multivalent display,f or example,o fs iallyllactose [21] showing in vitro inhibition at micromolar ligand concentrations as well as protection of mice from infection. However, depending on their structure multivalent PA MAM scaffolds may also be cytotoxic. [17, 22, 23] Promisingly,b iocompatible polyglycerol (PG)-based SAnanoparticles have been shown to reduce viral infection in vitro by up to 80 %w hen applied in millimolar ligand, respectively submicromolar nanoparticle concentrations. [8] Thei mportance of low receptor density and larger particle size was emphasized in this study similar to the PA MAM study. [21] Alternative ligands to SA are peptides targeting HA. [24] [25] [26] Peptides may have several advantages,i ncluding higher affinity and selectivity.They can be produced and conjugated to different polymeric scaffolds by straightforward synthetic methods as opposed to often synthetically challenging routes for stereochemically defined SA building blocks.P eptide affinity towards receptors can be easily optimized by phage display,m icroarray screening, [27] [28] [29] as well as chemical modification.
[ Indeed, in 2006 ap eptide derived from the signal sequence of fibroblast growth factor 4( FGF 4) was shown to inhibit infection by the influenza virus. [25] Thereafter, ap eptide was optimized for HA binding by selection from ap hage-displayed random peptide library. [24] This work also showed am ultivalent improvement of its binding properties by conjugation to either an amphiphilic N-stearoyl derivative, which formed self-assembled multivalent structures with enhanced binding capabilities or by presenting up to six peptide copies on ac arbosilane dendrimer. [24, 30, 31] We recently reported on apeptide (PeB) derived from the CDR domain of aH Ab inding antibody which binds in proximity to the SA binding pocket of HA. Theb inding property of PeB was improved upon MD simulations and microarray screening,l eading to the double mutant PeB GF , which binds to HA in the micromolar range. [32] In line with the self-assembly strategy,w es ynthesized amphiphilic stearoylPeB GF to form an oncovalent multivalent receptor construct. [33] Unfortunately,stearoyl-PeB GF did not form defined micelles.Weobserved structures,such as sheets and fibers.As such scaffolds are not able to retain their structural integrity in ac ellular (membrane) environment it challenges the general applicability of the self-assembly strategy for the design of multivalent antiviral peptides.
Herein, we introduce covalent conjugates of peptidic ligands and ab iocompatible PG-based hydrophilic dendritic scaffold to provide uniform and structurally stable multivalent inhibitors,w hich turn out to be high affinity virus binders with low toxicity in cellular as well as in animal models.F or synthesis of dendritic peptide-PG scaffold we envisioned the conjugation of an alkyne equipped HA binding PeB variants to ad endritic azido-PG [34] by Cu catalyzed alkyne azide cycloaddition (CuAAC) [35] (Figure 1 ). PeB and PeB GF were synthesized by solid-phase peptide synthesis with afinal N-terminal coupling of 4-pentynoic acid. To identify the optimal scaffold for amultivalent inhibitor,we chose dendritic PGs with different molecular weights and degrees of azide functionalization for peptide conjugation. CuAACw as carried out in basic ammonium bicarbonate buffer at room temperature overnight and the reaction mixture was pre-purified by dialysis,f ollowed by size exclusion chromatography. [36] Thec onjugation products were analyzed by NMR spectroscopy and DLS to obtain the size and number of ligands for each peptide-polymer conjugate (Table 1a nd Supporting Information). Particles with large polymer backbone were visualized by cryo-TEM ( Figure S19-S21) . Note that the ligand number in Table 1i s an average,o wing to the polymeric molecular weight distribution of polyglycerol (see Table S1 ).
All compounds were tested for their binding inhibition potential with the hemagglutination inhibition assay (HAI). [6] In short, we pretreated the IAVA ichi H3N2 (X31) with different concentrations of inhibitor and incubated this suspension with human erythrocytes. Virus binding to red blood cells was indicated by agglutination, which is visible as Figure 1 . a) Scheme for CuAAC coupling between peptide and polymer (for polymer sizes see Table 1 ). b) DLS data for the screening of different molecular-weight dendritic PGs conjugated with PeB peptides. [%]
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Diameter [d] [nm] gel in the well plate.T he lowest concentration of inhibitor that is able to inhibit agglutination was defined as inhibition constant (K i HAI ). With increasing size of the PG backbone,the K i HAI dropped to low nanomolar values as observed for dPGs with amolecular weight of 340 kDa (Figure 2and Table 2). A higher degree of functionalization (DF) did not substantially improve the inhibitory potential of the conjugates.Inone case higher valency even reduced the inhibitory effect (4c compared to 4b). In contrast to the monovalent case, [32] upon multivalent peptide presentation PeB GF was not superior to PeB in the HAI assay.N otably,u nspecific binding of the inhibitor to the cell membrane cannot be excluded, which would reduce the effective inhibitor concentration. Therefore,w eu sed microscale thermophoresis (MST) to measure directly the binding of inhibitors to IAV. To this end, we chose the best inhibitors 4b and 4d identified by the HAI assay displaying either PeB or PeB GF at low valency.M ST was conducted by titration against octadecyl rhodamine Bc hloride (R18) labeled X31 virus to derive apparent affinity constants (KD app )against intact virus,free in solution. While compound dPG 340 PeB 9 (4b)s howed aK D app of 36.6 mm (corresponding to 88.3 AE 13.6 nm of the multivalent nanoparticles), dPG 340 PeB GF 10 (4d) bound with 10-times higher affinity (3.1 mm peptide or 6.8 AE 1.1 nm multivalent nanoparticles) to the virus.
Theu nconjugated compound dPG 340 -azide (4a)d id not interact with the virus (Figure 2c ). This result confirms our previous findings for monomeric peptides,i nw hich PeB GF showed higher binding affinity towards X31 than the wildtype peptide PeB. [32] Interaction of dPG 340 PeB GF 10 (4d) with X31 Figure S21 ) PG 340 N 3 (4a)shows no binding (see Figure S20 ). Scale bars correspond to 100 nm. e) The marked image section of (d) (black frame) in detail, bound PG peptide conjugatesa re outlined in yellow,v irions are outlined in blue and the corona formed by HA is marked with ared dashed line. virus was also detected by cryo-TEM (Figure 2d ,e and Figure S21 ), while the unconjugated inhibitor did not interact with the virus ( Figure S20 ). We investigated the infection-inhibition potential of all the peptide-PG conjugates in acell-viability assay (Figure 3 ) after infecting MDCK II cells with av irus-inhibitor mixture. Cell viability was recorded with aMTS cell proliferation assay to determine viral-infection inhibition post-infection. Notably,a ll tested peptide-PG conjugates were non-toxic,w hen tested in concentrations of up to 200 mm peptide ( Figure S17 ). In accordance with the HAI assay,p eptide presentation on larger scaffolds substantially increased the inhibitory potential as evident by comparing the dissociation constants.W e attribute this observation to the steric-shielding character of the multivalent scaffolds,which can contribute additionally to the affinity of amultivalent compound. [37] We found that best inhibitors were PG 340 conjugates with alow DF for both, the PeB (4b)and PeB GF (4d). Both were able to inhibit infection at nanomolar peptide and picomolar nanoparticle concentrations,respectively (Figure 3and Table 2 ) corresponding to amultivalent enhancement of inhibition by afactor of 129 for PeB and 136 for PeB GF for the multivalently presented peptides compared to the monovalent peptide (see Supporting Information). We also monitored viral nucleoprotein (NP) expression in MDCK II cells infected with X31 pretreated with the inhibitors 4b and 4d.
While untreated virus at MOI 0.1 infected approximately 70 %o ft he cells,t he virus treated with inhibitor concentrations as low as 33 mm peptide (corresponding to 79 nm 4b and 71 nm 4d)r educed viral NP expression significantly to less than 10 %i nfected cells (Figure 3c and Figure S18 ). Tr eatment of virus with the control inhibitor dPG 340 N 3 (4a) did not lead to significant reduction of viral NP expression. After these promising results,weaimed to probe the peptide-PG conjugates 4b and 4d in in vivo experiments.S edated 8-weeks old BALB/c mice (body weight ca. 20 g) were infected upon an intranasal administration of an inhibitor-virus mix and their body weight monitored daily for 10 days.
After infection of mice with X31, illness is manifested, beside other symptoms,byaloss in body weight, which peaks at day 4-5 followed upon af ull recovery starting on day 10 (see infected, PBS treated control, Figure 3d ).
While the control construct dPG 340 N 3 (4a)did not protect from infection (body weight loss), mice treated with as ingle dose dPG 340 PeB 9 (4b;1 1.5 nmol kg À1 )m aintained their body weight until day 4( Figure 3d ). As imilar dosage with the dPG 340 PeB GF 10 (4d)w as not feasible owing to solubility problems at higher concentrations.W esurmise that asecond inhibitor dosing on day 4w ould be necessary to continue protection from infection. However,such aprocedure would need another sedation step,which causes additional stress to the mice.Analternative way of repetitively dosing would be the use of aerosol chambers.L ower inhibitor dosages with both inhibitors at about 2nmol kg À1 concentrations did not significantly protect from infection.
Nevertheless,m ice treated with dPG 340 PeB 9 (4b)w ere protected to as ubstantially higher extent than those treated with dPG 340 PeB GF 10 (4d)a ts imilar inhibitor dosage.W e cannot exclude that PeB GF -coated nanoparticles bind to respiratory structures or undergo cellular uptake in the respiratory tract, interfering with virus inhibition.
Notably,t he efficiency of dPG 340 PeB 9 (4b;1 1.5 nmol nanoparticles per kg or 4.8 mmol PeB per kg) in protecting mice from infection of was about ten times higher than multivalent siallyllactose (SL) presenting PA MAM dendrimers (50 mmol SL per kg). [21] In summary,wefound that amultivalent covalent display of influenza HA binding peptides PeB and PeB GF drastically enhances the antiviral potency in vitro.T his potencyi s provided by both the high affine binding as well as the steric character of large polymers.A lthough PGs decorated with PeB GF showed higher affinity compared to those conjugated to PeB in various in vitro assays,w ed iscovered that the corresponding PG-PeB conjugates are even more potent multivalent inhibitors and even active in vivo at low nmol kg À1 single-dose administration. Thus,wepresent herein for the first time,non-toxic influenza virus inhibitors based on amultivalent covalent peptide display on dendritic polymers. These findings pave the way for opportunities for peptidenanoparticles in future drug development against multivalent targets,s ince they can be obtained by straightforward synthetic methods while showing high affinity and low toxicity.M ost importantly,p eptide ligands can be evolved and further modified to bind to different receptors,w hich in concert with nanoparticle engineering,a sd emonstrated in this study,o pens further avenues to target other diseaserelevant multivalent receptors than the one studied herein.
